Four antibiotic compounds produced in Streptomyces bacteria attack multiple parts of an essential metabolic pathway.

de la Fuente-Nunez is a presidential associate professor at the University of Pennsylvania. Skinner is CEO of the AMR Action Fund. Of all the areas of drug development that artificial intelligence has ...

VeriSIM Life was founded to solve that problem. The company's core platform, BIOiSIM, is a hybrid mechanistic-AI system that integrates mechanistic quantitative models and machine learning into a ...

Antibiotics are a crucial tool in the fight against bacterial infections. But the World Health Organization has long warned that we are facing an antibiotic crisis. Bacteria can easily adapt, evolve, ...

June 22 (Reuters) - The U.S. Food and Drug Administration said on Monday it is launching a series of measures to speed up ...

Wockhardt's Zaynich has received US FDA approval, becoming India's first indigenously developed novel antibiotic approved in ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...

Scientists from the University of Tübingen and Monash University studied glycopeptide antibiotics, a key resource in countering drug-resistant pathogens, to uncover their evolutionary origins to gain ...

Companies see a commercial opportunity in creating new ways to administer drugs to patients – in space.

As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How ...